Market closedNon-fractionalADR
BioNTech SE/BNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker
BNTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Mainz, Germany
Employees
6,133
Website
www.biontech.com
BioNTech SE Metrics
BasicAdvanced
$24B
Market cap
195.10
P/E ratio
$0.52
EPS
0.26
Beta
-
Dividend rate
Price and volume
Market cap
$24B
Beta
0.26
52-week high
$125.83
52-week low
$85.21
Average daily volume
15
Financial strength
Current ratio
11.379
Quick ratio
11.164
Long term debt to equity
1.027
Total debt to equity
1.183
Management effectiveness
Return on assets (TTM)
0.51%
Return on equity (TTM)
0.56%
Return on investment (TTM)
0.55%
Valuation
Price to earnings (TTM)
195.096
Price to revenue (TTM)
8.082
Price to book
1.105
Price to tangible book (TTM)
1.175
Price to free cash flow (TTM)
4.462
Growth
Revenue change (TTM)
-77.65%
Earnings per share change (TTM)
-98.08%
3-year revenue growth (CAGR)
99.31%
3-year earnings per share growth (CAGR)
299.76%
What the Analysts think about BioNTech SE
Analyst Ratings
Majority rating from 19 analysts.
BioNTech SE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€188M
-87.32%
Net income
-€315M
-168.81%
Profit margin
-167.96%
-642.51%
BioNTech SE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€0.79
€0.67
€1.90
-€1.31
-
Expected
-€0.96
-€0.10
€2.42
-€1.09
-€2.03
Surprise
-17.61%
-796.10%
-21.50%
20.64%
-
BioNTech SE News
AllArticlesVideos
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
Reuters·2 days ago
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
GlobeNewsWire·5 days ago
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $24B as of July 27, 2024.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 195.1 as of July 27, 2024.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell BioNTech SE stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.